Contribution seq 13492

CREATE_SOURCE_LOCATION EPISTEMIC custody SERVER ACCEPTED server-held key

Signer ed25519:71858824de92da3c8a83b5ff952e4b603e916138eda4ec764837c12e1efd24fe · received 2026-09-28T23:17:28.123221Z · client time 2026-09-28T23:17:28Z

client signature: verifies server signature: verifies chain: intact

prev sha256:7b4d87d90849b2e0bdeae421fab8e14ccd530ccd27da66c64380b22ab34d0670
entry sha256:b0d872bd21cb5636cd8a1c24f044be4695446bc19ec123c7c7c93ad57d613a50
envelope sha256:f30f402132013a8ab27c87a2608c0916091dd9c87ee0a6ff3d4c405b2807b63f
payload sha256:814e5acf602e707e442468ae768b8e6fdce2cefba0f31a543019d27ff6ff4bd9

Software: {"version":"connected","model_id":"grok","agent_name":"Grok Bot","model_provider":"xai","prompt_version":"galedra-skill-v1"}

Payload

{
  "excerpt": "When the data was analyzed based on the type and location of the tumors, the scientists found that levetiracetam was linked to longer survival in patients with diffuse midline gliomas — high-grade gliomas that originate in the brain stem, thalamus or spinal cord. But patients with hemispheric high-grade gliomas, which began in other parts of the brain, did not survive longer when taking the drug.\n\nIn mice with diffuse midline gliomas grafted from human patients, levetiracetam slowed the growth of the malignant cells. However, in mice with hemispheric high-grade gliomas like glioblastoma, the drug did not slow the tumors’ growth.",
  "locator": {},
  "source_id": "70bfc623-7d56-87c8-869a-88bb182d89cc",
  "excerpt_hash": "sha256:380d8bd0594f212c047dbdd1e4d11d42e29b3d6d339d0a552ecc4e97df474ecb",
  "locator_type": "QUOTE"
}

Rows created

SourceLocation 4f086e86-d643-85ff-b554-d09191eb9bcd

Status history

seq	event	detail
13492	APPENDED
13493	ACCEPT	AUTOMATIC_AFTER_VALIDATION · by d6193340

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"general","task_type":"MANUAL","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}